U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C9H13NO.BrH
Molecular Weight 232.118
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GEPEFRINE HYDROBROMIDE, (±)-

SMILES

Br.CC(N)CC1=CC(O)=CC=C1

InChI

InChIKey=GTBIZADMZLFAFS-UHFFFAOYSA-N
InChI=1S/C9H13NO.BrH/c1-7(10)5-8-3-2-4-9(11)6-8;/h2-4,6-7,11H,5,10H2,1H3;1H

HIDE SMILES / InChI

Molecular Formula BrH
Molecular Weight 80.912
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C9H13NO
Molecular Weight 151.2056
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Gepefrine (Pressionorm and Wintonin) is an antihypotensive agent. It was used for therapy of orthostatic dysregulation. One hour after oral administration of 30 mg or 45 mg gepefrine the blood pressure increased significantly at rest and more markedly on standing and during the step test. Gepefrine led to a reduction in pathological orthostatic regulation during the early phase as well as to the prevention of subjective and objective signs of orthostatic adjustment disorder during the late phase. Patients with insufficient rise in blood pressure during the step test (80 watts) showed after gepefrine a distinct tendency towards normalisation and the regression of subjective states of exhaustion. Gepefrine caused on average no substantive alternations in heart rate during all phases of the investigation. Complications or side-effects due to the method or the medicament were not observed.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
PubMed

PubMed

TitleDatePubMed
[Therapy of orthostatic dysregulation. Comparative studies on anti-hypotensive sympathomimetics with a tilt-table test].
1980 Aug 7
[Therapy of orthostatic dysregulation with gepefrin. Study with continuous telemetric blood pressure monitoring].
1985 Apr
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: The action of the pressor agent gepefrine (D form of 3-hydroxyphenyl-2-aminopropan) was evaluated in 16 patients with typical clinical symptoms of orthostatic adjustment disorders
One hour after oral administration of 30 mg or 45 mg gepefrine the blood pressure increased significantly at rest and more markedly on standing and during the step test.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:39:35 GMT 2023
Edited
by admin
on Sat Dec 16 11:39:35 GMT 2023
Record UNII
12X3X9361J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GEPEFRINE HYDROBROMIDE, (±)-
Common Name English
PHENOL, 3-(2-AMINOPROPYL)-, HYDROBROMIDE (1:1)
Systematic Name English
(±)-3-HYDROXYAMPHETAMINE HYDROBROMIDE
Systematic Name English
Code System Code Type Description
CAS
1391054-33-3
Created by admin on Sat Dec 16 11:39:35 GMT 2023 , Edited by admin on Sat Dec 16 11:39:35 GMT 2023
PRIMARY
PUBCHEM
71748807
Created by admin on Sat Dec 16 11:39:35 GMT 2023 , Edited by admin on Sat Dec 16 11:39:35 GMT 2023
PRIMARY
FDA UNII
12X3X9361J
Created by admin on Sat Dec 16 11:39:35 GMT 2023 , Edited by admin on Sat Dec 16 11:39:35 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE